172 related articles for article (PubMed ID: 32117279)
1. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity.
Koliesnik IO; Kuipers HF; Medina CO; Zihsler S; Liu D; Van Belleghem JD; Bollyky PL
Front Immunol; 2020; 11():132. PubMed ID: 32117279
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
Brennan TV; Lin L; Brandstadter JD; Rendell VR; Dredge K; Huang X; Yang Y
J Clin Invest; 2016 Jan; 126(1):207-19. PubMed ID: 26649979
[TBL] [Abstract][Full Text] [Related]
3. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
[TBL] [Abstract][Full Text] [Related]
4. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
5. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
7. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.
Dredge K; Hammond E; Handley P; Gonda TJ; Smith MT; Vincent C; Brandt R; Ferro V; Bytheway I
Br J Cancer; 2011 Feb; 104(4):635-42. PubMed ID: 21285983
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells.
Luz-Crawford P; Kurte M; Bravo-Alegría J; Contreras R; Nova-Lamperti E; Tejedor G; Noël D; Jorgensen C; Figueroa F; Djouad F; Carrión F
Stem Cell Res Ther; 2013 Jun; 4(3):65. PubMed ID: 23734780
[TBL] [Abstract][Full Text] [Related]
9. PI-88 and Related Heparan Sulfate Mimetics.
Chhabra M; Ferro V
Adv Exp Med Biol; 2020; 1221():473-491. PubMed ID: 32274723
[TBL] [Abstract][Full Text] [Related]
10. Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses.
Quan MY; Song XJ; Liu HJ; Deng XH; Hou HQ; Chen LP; Ma TZ; Han X; He XX; Jia Z; Guo L
J Neuroinflammation; 2019 Mar; 16(1):52. PubMed ID: 30823934
[TBL] [Abstract][Full Text] [Related]
11. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Joller N; Lozano E; Burkett PR; Patel B; Xiao S; Zhu C; Xia J; Tan TG; Sefik E; Yajnik V; Sharpe AH; Quintana FJ; Mathis D; Benoist C; Hafler DA; Kuchroo VK
Immunity; 2014 Apr; 40(4):569-81. PubMed ID: 24745333
[TBL] [Abstract][Full Text] [Related]
12. Primaquine elicits Foxp3
Thome R; Casella G; Lotfi N; Ishikawa LWL; Wang Q; Ciric B; Zhang GX; Rostami A
J Autoimmun; 2020 Nov; 114():102505. PubMed ID: 32595012
[TBL] [Abstract][Full Text] [Related]
13. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections.
Chhabra M; Wilson JC; Wu L; Davies GJ; Gandhi NS; Ferro V
Chemistry; 2022 Feb; 28(11):e202104222. PubMed ID: 34981584
[TBL] [Abstract][Full Text] [Related]
14. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.
Yang H; Zhang Y; Wu M; Li J; Zhou W; Li G; Li X; Xiao B; Christadoss P
Inflamm Res; 2010 Mar; 59(3):197-205. PubMed ID: 19768385
[TBL] [Abstract][Full Text] [Related]
15. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
Ray U; Thirusangu P; Jin L; Xiao Y; Pathoulas CL; Staub J; Erskine CL; Dredge K; Hammond E; Block MS; Kaufmann SH; Bakkum-Gamez JN; Shridhar V
Oncogene; 2023 Sep; 42(37):2725-2736. PubMed ID: 37550562
[TBL] [Abstract][Full Text] [Related]
16. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
17. Recovery Profiles of T-Cell Subsets Following Low-Dose Total Body Irradiation and Improvement With Cinnamon.
Zheng X; Guo Y; Wang L; Zhang H; Wang S; Wang L; An L; Zhou X; Li X; Yao C
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1118-26. PubMed ID: 26475064
[TBL] [Abstract][Full Text] [Related]
18. PDCD5 negatively regulates autoimmunity by upregulating FOXP3(+) regulatory T cells and suppressing Th17 and Th1 responses.
Xiao J; Liu C; Li G; Peng S; Hu J; Qu L; Lv P; Zhang Y; Ma D; Chen Y
J Autoimmun; 2013 Dec; 47():34-44. PubMed ID: 24012345
[TBL] [Abstract][Full Text] [Related]
19. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets.
Pianta S; Bonassi Signoroni P; Muradore I; Rodrigues MF; Rossi D; Silini A; Parolini O
Stem Cell Rev Rep; 2015 Jun; 11(3):394-407. PubMed ID: 25348066
[TBL] [Abstract][Full Text] [Related]
20. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis.
Liu JQ; Liu Z; Zhang X; Shi Y; Talebian F; Carl JW; Yu C; Shi FD; Whitacre CC; Trgovcich J; Bai XF
J Immunol; 2012 Apr; 188(7):3099-106. PubMed ID: 22387555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
